Affiliation:
1. State Key Laboratory of Advanced Medical Materials and Devices Tianjin Key Laboratory of Biomedical Materials Key Laboratory of Biomaterials and Nanotechnology for Cancer Immunotherapy Institute of Biomedical Engineering Chinese Academy of Medical Sciences and Peking Union Medical College Tianjin 300192 China
2. Tianjin Key Laboratory of Radiation Medicine and Molecular Nuclear Medicine Institute of Radiation Medicine Chinese Academy of Medical Sciences and Peking Union Medical College Tianjin 300192 China
Abstract
AbstractCaused by the loss in the tolerance against self‐antigens, autoimmune diseases are chronic disorders that impact millions of individuals annually with significant economic burden. They are triggered by a deficiency in the quantity or function of regulatory T (Treg) cells, which are essential for maintaining self‐tolerance and preventing excessive immune responses. Several clinical trials over the past decade have demonstrated the safety and feasibility of certain Treg cell‐based therapies against autoimmune diseases, inspiring optimism among patients. Studies have indicated that targeted cell pharmaceuticals are significantly promising, offering superior targeting, improved biocompatibility, and prolonged blood circulation. Thus, Treg cell‐based delivery systems are also extensively studied. This review describes the role of Treg cells in the immune system both in homeostasis and in the development of autoimmunity, purification and expansion methods, derived cell pharmaceutical therapies, and the therapeutic potential for autoimmune diseases, beneficial to accelerating the industrialization and clinical translation of formulations based on Treg cells.
Funder
National Key Research and Development Program of China
National Natural Science Foundation of China
Fundamental Research Funds for the Central Universities
Natural Science Foundation of Tianjin Municipality